AVITA Medical, Inc. (ASX:AVH)
| Market Cap | 714.36M +309.2% |
| Revenue (ttm) | 121.77M +17.0% |
| Net Income | -51.94M |
| EPS | -1.75 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 278,644 |
| Open | 4.510 |
| Previous Close | 4.620 |
| Day's Range | 4.400 - 4.520 |
| 52-Week Range | 1.000 - 5.170 |
| Beta | 2.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About AVITA Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.
Financial numbers in USD Financial StatementsNews
Avita Medical announces complete results from Cohealyx I study
Avita Medical (RCEL) announced complete results, including six-month follow-up, from its Cohealyx I study in patients with full-thickness wounds. The findings extend the previously reported evidence o...
AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes
Complete Cohealyx I data show earlier graft readiness, healing and improved scar scores through six months with no product-related adverse events reported
Avita Medical price target raised to $22 from $20 at TD Cowen
TD Cowen raised the firm’s price target on Avita Medical (RCEL) to $22 from $20 and keeps a Buy rating on the shares. The firm said the company’s post-3Q investor…
AVITA Medical Transcript: Investor update
Q3 revenue was $26.1m and FY26 guidance rose to $92m-$94m, with Q4 cash flow breakeven reaffirmed. Management cited margin gains, broader product adoption and reimbursement changes supporting growth.
AVITA Medical Slides: Investor update
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Nov. 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transfor...
Avita Medical price target raised to $20 from $12 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on Avita Medical (RCEL) to $20 from $12 and keeps a Buy rating on the shares. Q3 was a “blowout,”…
Avita Medical price target raised to $21 from $15 at BTIG
BTIG raised the firm’s price target on Avita Medical (RCEL) to $21 from $15 and keeps a Buy rating on the shares after its Q3 results. The company’s earnings beat…
AVITA Medical Earnings Call Transcript: Q3 2026
Q3 revenue rose 53% YoY to $26.1M, while gross margin expanded to 84% and net cash use fell to $0.6M. FY2026 revenue guidance increased to $92M–$94M, with Q4 cash flow breakeven reaffirmed.
AVITA Medical Earnings release: Q3 2026
AVITA Medical released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q3 2026
AVITA Medical has published its Q3 2026 quarterly earnings report on November 5, 2026.
AVITA Medical Slides: Q3 2026
AVITA Medical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
AVITA Medical Reports Third Quarter Results
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a l...
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Me...
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transfor...
Avita Medical price target raised to $15 from $11 at BTIG
BTIG raised the firm’s price target on Avita Medical (RCEL) to $15 from $11 and keeps a Buy rating on the shares as part of a broader research note previewing…
AVITA Medical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership emphasized operational focus and disciplined execution, driving strong sequential growth and improved financials. The company is deepening penetration in existing accounts, expanding its product portfolio, and targeting cash flow breakeven by Q4 2026, with significant market opportunity ahead.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced t...
Avita Medical price target raised to $12 from $8 at Lake Street
Lake Street raised the firm’s price target on Avita Medical (RCEL) to $12 from $8 and keeps a Buy rating on the shares following “positive” PermeaDerm 1 trial results. While…
Avita Medical price target raised to $14 from $12 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Avita Medical (RCEL) to $14 from $12 and keeps a Buy rating on the shares. The firm hosted a…
Avita Medical price target raised to $11 from $7 at BTIG
BTIG raised the firm’s price target on Avita Medical (RCEL) to $11 from $7 and keeps a Buy rating on the shares. The firm is adjusting its model after the…
AVITA Medical Transcript: KOL event
PermeaDerm demonstrated a 70% cost reduction and comparable clinical outcomes to allograft, with high surgeon and patient satisfaction. Surgeons reported workflow and supply advantages, no safety concerns, and broad applicability, supporting a shift toward integrated wound care platforms.
AVITA Medical Press release: KOL event
AVITA Medical issued a press release on August 18, 2026, disclosing material business information to investors.
AVITA Medical Slides: KOL event
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Avita Medical reports PermeaDerm-I clinical study meets primary endpoint
Avita Medical (RCEL) announced results from its multicenter, randomized controlled PermeaDerm-I clinical study demonstrating PermeaDerm, a biosynthetic wound matrix, delivered clinically comparable ou...